Document is current
Any future updates will be listed below
-
Authors
Castle, Alison C. https://orcid.org/0000-0001-7752-6236
Busang, Jacob
Dreyer, Jaco
Herbst, Carina
Okesola, Nonhlanhla
Chimbindi, Natsayi
Zuma, Thembelihle
Jarolimova, Jana
Hahn, Judith A.
Psaros, Christina
Shenoi, Sheela V.
Shahmanesh, Maryam
Siedner, Mark J.
-
Funding
Funding for this research was provided by:
Fogarty International Center (D43 TW010543)
National Institute of Allergy and Infectious Diseases (T32 AI007433)
National Heart, Lung, and Blood Institute (K24 HL166024)
National Institute of Mental Health (R01MH114560)
National Institute on Alcohol Abuse and Alcoholism (K24 AA022586)
Wellcome Trust (201433/Z/16/A)
- License Information
-
More Information
Article History
Accepted: 19 March 2025
First Online: 5 April 2025
Declarations
:
: Dr. Hahn served as a consultant for Pear Therapeutics in 2022. All other authors declare no competing interests that are relevant to the content of this article.
: The institutional review boards approved the Isisekelo Sempilo study at the University of KwaZulu-Natal Biomedical Research Ethics Committee (BREC/00000473/2019) and University College London Research Ethics Committee (5672/003).
: Written informed consent was obtained from participants aged 18–29 years; written assent was obtained from participants aged 16–17 years, with written consent from their parents or guardian.
